Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda

PHASE4CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 28, 2017

Study Completion Date

April 28, 2017

Conditions
HIV/AIDS and Infections
Interventions
BIOLOGICAL

Hepatitis B vaccine

An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol

Trial Locations (1)

Unknown

Mulago National referral hospital, Kampala

All Listed Sponsors
collaborator

Makerere University

OTHER

collaborator

Uganda Cancer Institute

OTHER

lead

Fred Hutchinson Cancer Center

OTHER

NCT02316444 - Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda | Biotech Hunter | Biotech Hunter